CEA (Carcinoembryonic Antigen)
| Clinical | Optimal | |
|---|---|---|
| Male | 0.0 - 5.0 µg/L | <5.0 µg/L (non-smokers <3.0 µg/L) |
| Female | 0.0 - 5.0 µg/L | <5.0 µg/L (non-smokers <3.0 µg/L) |
What is CEA (Carcinoembryonic Antigen)?
Carcinoembryonic Antigen (CEA) is a glycoprotein that is produced in large quantities during foetal development but normally only present at very low levels in healthy adults. It is classified as a tumour marker because elevated levels can be associated with certain cancers, particularly colorectal cancer.
CEA is not specific to cancer — it can also be elevated in a range of benign conditions including smoking, inflammatory bowel disease, liver disease, pancreatitis, and certain lung conditions. This lack of specificity means CEA is not recommended as a screening test for cancer in the general population.
CEA's primary clinical utility is in monitoring patients who have already been diagnosed with colorectal cancer. Serial measurements following surgery or chemotherapy can help detect recurrence early, often before symptoms or imaging findings become apparent.
Why CEA (Carcinoembryonic Antigen) Matters for Your Health
CEA is a valuable biomarker when used in the appropriate clinical context. For individuals with a history of colorectal, pancreatic, breast, lung, or ovarian cancer, tracking CEA levels over time can provide early warning of disease recurrence, allowing for timely intervention.
For general health monitoring, CEA can serve as one piece of a broader cancer-awareness strategy, particularly for those with a family history of colorectal cancer. However, it is crucial to understand that a normal CEA does not exclude cancer, and an elevated CEA does not confirm it.
In the context of preventive health, any unexpected elevation in CEA should prompt further investigation rather than cause alarm. Many benign conditions can raise CEA, and the trend over time is often more informative than a single measurement.
CEA (Carcinoembryonic Antigen)& Your Wearable Data
Carcinoembryonic antigen (CEA) is a tumour marker primarily used for monitoring colorectal cancer treatment response and detecting recurrence. It is not recommended as a standalone screening tool due to limited sensitivity and specificity. CEA can be mildly elevated in smokers, inflammatory bowel disease, and some benign conditions.
While wearable devices have no direct relationship with CEA levels, maintaining overall health through regular physical activity, adequate sleep, and stress management — all tracked by your wearable — supports the general health vigilance that includes appropriate cancer screening. Regular exercise is associated with reduced colorectal cancer risk, providing an additional motivation for the active lifestyle your wearable tracks.
What High CEA (Carcinoembryonic Antigen) May Suggest
Elevated CEA may suggest colorectal cancer, particularly if levels are significantly raised (above 10 µg/L). However, more modest elevations are frequently seen in benign conditions including smoking (the most common cause of mildly elevated CEA), inflammatory bowel disease, liver cirrhosis, pancreatitis, hypothyroidism, and peptic ulcers.
Other cancers that may raise CEA include pancreatic, breast, lung, gastric, and ovarian cancers. In known cancer patients, a rising CEA trend is often more significant than a single elevated value.
If results suggest elevated CEA without a known cancer diagnosis, your GP may recommend repeat testing, further investigation based on clinical context (such as colonoscopy for bowel symptoms), and review of potential benign causes. Smoking cessation should be advised, as CEA typically falls within weeks of stopping.
What Low CEA (Carcinoembryonic Antigen) May Suggest
Low or undetectable CEA is a normal finding and generally indicates a low risk of the conditions associated with elevated CEA. In patients being monitored after cancer treatment, sustained low CEA levels are reassuring and suggest no evidence of recurrence.
It is important to note that some cancers, particularly early-stage and poorly differentiated tumours, may not produce elevated CEA. Therefore, a normal CEA cannot be used to exclude a cancer diagnosis.
Low CEA levels do not require any action or follow-up in the general population.
How to Optimise Your CEA (Carcinoembryonic Antigen)
Food
Support overall cancer risk reduction with a diet rich in diverse vegetables, fruits, whole grains, and legumes. Include cruciferous vegetables (broccoli, cauliflower, Brussels sprouts) which contain cancer-protective sulforaphane. Consume adequate dietary fibre (at least 30g daily) to support bowel health, as fibre intake is inversely associated with colorectal cancer risk. Limit processed and red meat intake to no more than 70g per day (UK NHS guidance). Include garlic and onions, which contain allicin and other compounds with anti-cancer properties.
Lifestyle
Stop smoking, as this is the most impactful action for reducing CEA levels and cancer risk. Maintain a healthy body weight, as obesity increases the risk of several cancers associated with elevated CEA. Engage in at least 150 minutes of moderate exercise per week, which is associated with reduced colorectal cancer risk. Limit alcohol consumption, as alcohol is a known carcinogen. Participate in NHS cancer screening programmes when eligible, including bowel cancer screening from age 50.
Supplements
Vitamin D3 supplementation may support cancer risk reduction, as low vitamin D status has been associated with increased colorectal cancer risk. Curcumin (turmeric extract) has shown anti-inflammatory and potentially anti-cancer properties in laboratory studies. A high-quality fibre supplement (such as psyllium husk) can complement dietary fibre intake for bowel health.
When to Speak to Your GP
See your GP if CEA is elevated above 5.0 µg/L, particularly if you are a non-smoker, have bowel symptoms (change in bowel habit, blood in stools, unexplained weight loss), or have a personal or family history of cancer. Significantly elevated CEA (above 10 µg/L) warrants prompt investigation. If you have a history of cancer, report any rising CEA trend to your oncologist or specialist nurse.
References
- NHS. Bowel cancer — Diagnosis. Updated 2024. nhs.uk
- NICE. Colorectal cancer — NICE guideline NG151. nice.org.uk
- BMJ. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47(4):624-630. pubmed.ncbi.nlm.nih.gov
- ASCO. Locker GY, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313-5327. pubmed.ncbi.nlm.nih.gov
Medical Disclaimer— This content is for general educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Omniwo Ltd is a wellness information service and is not a medical device, clinical laboratory, or regulated healthcare provider under MHRA guidelines. The “optimal ranges” presented on this page are based on published clinical guidelines (WHO, NICE, NHS) and peer-reviewed research; they represent functional wellness targets and may differ from standard laboratory reference ranges. Individual results should always be interpreted by a qualified healthcare professional (such as your GP) who understands your full medical history. Do not start, stop, or change any medication or supplement based solely on this information. If you are experiencing symptoms, seek medical attention promptly.